“Mavacamten” became the first cardiac myosin inhibitor oral heart disease drug to be permitted for use in the US.The US FDA approved “Mavacamten” for the treatment ofobstructive hypertrophic cardiomyopathy. 

Adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy will be treated with "Mavacamten." According to the American Heart Association, about one in every 500 people in the United States has hypertrophic cardiomyopathy, with obstructive hypertrophic cardiomyopathy accounting for the majority of cases.

Mavacamten lowers left ventricular ejection fraction and can cause systolic dysfunction, which can lead to heart failure. The FDA has issued a strong warning since the drug includes a boxed warning on the label to keep the users aware of the serious or life-threatening risks of a drug. (Reuters, April 29, 2022)